The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2025

Filed:

Feb. 09, 2022
Applicant:

Actinium Pharmaceuticals, Inc., New York, NY (US);

Inventor:

Dale L Ludwig, Rockaway, NJ (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 51/10 (2006.01); C07K 14/725 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 51/1045 (2013.01); C07K 14/7051 (2013.01); C07K 16/2809 (2013.01); C07K 16/2833 (2013.01); A61K 38/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2319/33 (2013.01);
Abstract

Radionuclide-labeled soluble biologics directed against peptide presenting Major Histocompatibility Complexes (pMHCs), and methods for treating cancers using the biologics are provided. Soluble biologics include recombinant T-cell receptor proteins (rTCR) and TCR-antibody mimics that specifically bind to pMHCs. The soluble biologics may further include a heavy chain of IgG1, IgG2, IgG4, or variants thereof. The radioisotopes used to label the soluble biologic may include alpha-emitting isotopes, such as actinium-225, or beta-emitting isotopes, such as lutetium-177, and may be administered at a maximum tolerated dose in a single bolus or in fractionated doses that together equal the maximum tolerated dose. The methods may further include administration of additional therapeutic agents or modalities.


Find Patent Forward Citations

Loading…